|
|
|
|
|
|
People: |
ACYTE Board |
Prof. Peter Gray
CEO, Co-founder of ACYTE
BSc (Sydney), PhD (UNSW),
FTSE, FAICD
Email: info@acyte.com.au
|
Peter Gray is Director of the Australian Institute for Bioengineering and Nanotechnology and Professor of Bioengineering at the University
of Queensland, and Emeritus Professor of Biotechnology at the
University of NSW. He has had commercial experience in the
USA working for Eli Lilly and Co and the Cetus Corporation,
and has held academic positions at University of College
London and at the University of California, Berkeley. He has
built up R&D capabilities in mammalian cell culture to be the
leading group in Australia, with an extensive collaborative
network of international research groups and corporations.
Prof Gray serves on a number of Boards and is involved in a
wide range of international Biotechnology activities. He has served as
a member of the Pharmaceutical Sub-Committee of the Therapeutic
Goods Administration (TGA) Australia and is one of the
founders and a past President of the Australian Biotechnology
Association, AusBiotech. Prof Gray is regularly
involved as an expert witness in biotechnology patent cases
and has extensive consulting experience. |
|
Dr Dean Moss, BSc, MPhil, PhD, GAICD.
|
Dr Dean Moss is the General Manager, Life Sciences at UniQuest Pty Ltd. UniQuest is the main commercialisation arm of The University of Queensland and has a staff of 90. Over its 25 year successful history, UniQuest has created over 60 start-up companies and generated significant licenses including the HPV vaccine Gardasil. Dean has a wealth of international life science knowledge and experience with more than 20 years experience in science, universities, business, management and commercialisation in Australia, USA and UK.
He has been Managing Director or a senior business development executive in several health and biotech companies worldwide, including Binax, Agen Biomedical, Launch Diagnostics, AMRAD ICT, AMRAD Biotech, United Drug and co-founded his own successful start-up business, York Medical Technologies Ltd in the UK. Prior to moving into the commercial world, Dean was principal R&D scientist at Agen Biomedical.
After finishing his PhD with The University of Queensland, Dean worked as an NHMRC research scientist in Brisbane at the Princess Alexandra Hospital, the Royal Brisbane Hospital and the Queensland Institute of Medical Research. Dean was awarded the Campion-Ma-Playoust Memorial Award for Medical Research. He holds several Board roles including Acyte Pty Ltd, Coridon Pty Ltd, Bio Energy Solutions Pty Ltd (Chairman) and Q-Pharm Pty Ltd, and has contributed to raising over $20m in venture capital investment.
|
|
Mr. Stephen Denaro CA
|
Stephen had extensive experience in mergers and acquisitions, business valuations, accountancy services, and income tax compliance gained from positions as Company Secretary and Chief Financial Officer of various public companies, and with major chartered accountancy firms in Australia and the United Kingdom. He provides Company Secretarial services for a number of start up technology and public companies.
Stephen has a Bachelor of Business in Accountancy, Graduate Diploma in Applied Corporate Governance, and is a member of the Institute of Chartered Accountants in Australia, and the Australian Institute of Company Directors.
|
|
Dr Alfredo Martinez-Coll
|
Dr Alfredo Martinez-Coll Alfredo graduated with a B.Sc. in Biomedical Engineering (minor in artificial organ design) in 1986 from Louisiana Tech University (USA). He has more than 16 years experience in biomedical research in Venezuela, the United States, and Australia covering design of artificial organs, cardiovascular and cerebrovascular physiology, membrane transport, and oxygen transport to tissue.
In 1995 Alfredo moved to Australia and joined the Cooperative Research Centre for Cardiac Technology (CRC-CT); obtaining his Doctorate from the University of Technology, Sydney in 1999, and completing his post-doctoral training with the Faculty of Engineering in 2003.
Alfredo has worked in the area of intellectual property and commercialisation of technology across a number of Area Health Services and academia for the last 7 years. In 2006 he joined NewSouth Innovations Pty Ltd- NSi (the commercialisation company of UNSW) where he is currently the Commercialisation Manager for the Faculty of Medicine. In 2008 and 2010 he was involved in significant equity transactions for investments into two NSi spin-off companies. Alfredo has been a member for the NSW Branch of the AusMedtech since 2008. His main areas of interest are sustainable funding for science, entrepreneurship, innovation, project management in science and business development -all part of a number of submissions to the State and Commonwealth governments.
|
|
Scientific Staff |
|
Trent's research involves
molecular engineering of mammalian cell lines for
improved Biopharmaceutical Development.
Trent obtained his PhD from the University of
Queensland in 2000. He then moved to
Harvard Medical School followed by 5 years working
at the Gurdon Institute, University of Cambridge.
Trent returned to Australia in 2006. Trent has manys years of experience in recombinant protein production and project management.
|
|
|
|
Dr Wooh heads the cell line research and development for Acyte.
She is involved developing the molecular biology research for
mammalian expression systems and liasing with downstream
processes for cell line and product development. She holds a
PhD in molecular endocrinology and molecular cell biology
from the University of Queensland at the Institute for
Molecular Bioscience. |
|
|
|
|
|
|
|
|
|
